Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Perioperative Management: A Systematic Review and Meta-Analysis
This systematic review and meta-analysis of 47 studies demonstrates that perioperative use of sodium-glucose cotransporter 2 inhibitors is associated with significantly reduced risks of acute kidney injury, new-onset atrial fibrillation, and mortality in specific surgical populations, while maintaining a favorable safety profile without excess adverse events.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, millions of people undergo surgeries or heart procedures that place immense stress on the body's internal systems. For those with diabetes, the challenge is twofold: managing blood sugar while protecting the kidneys and heart from the shock of the operation. One class of modern diabetes medication, known as sodium-glucose cotransporter 2 inhibitors, has already proven its worth in daily life by lowering the risk of heart failure and kidney disease. These drugs work by helping the kidneys remove excess sugar through urine, a process that also eases pressure within the kidney's filtering units and reduces inflammation. However, a long-standing debate has persisted in operating rooms: should doctors stop these medications before a procedure to avoid complications, or is it safer to keep patients on them to shield their organs from the trauma of surgery?
To answer this, researchers at Fuwai Shenzhen Hospital conducted a massive review of existing medical literature, gathering data from forty-seven different studies involving thousands of patients. They looked specifically at what happened to people who took these medications during the time surrounding their surgeries compared to those who did not. The team examined a wide range of procedures, from open-heart surgeries and valve replacements to less invasive catheter procedures and angiograms. Their goal was to determine if continuing the medication offered protection against acute kidney injury, irregular heart rhythms, or death, and whether it introduced new dangers like dangerously low blood sugar or a specific type of diabetic crisis.
The findings paint a clear picture of benefit. The analysis revealed that patients who continued taking these medications around the time of their procedures were significantly less likely to suffer from acute kidney injury, a sudden and dangerous drop in kidney function. This protective effect was particularly strong in patients undergoing transcatheter aortic valve replacement, a procedure where a new heart valve is inserted through a blood vessel, and in those undergoing open-heart surgery. In the latter group, a large randomized trial showed that a short course of the medication started just before surgery cut the risk of kidney injury nearly in half. The protection extended to patients receiving contrast dye for heart imaging as well, where the medication helped shield the kidneys from the toxic effects of the dye.
Beyond organ protection, the study found that keeping patients on these drugs was linked to better survival rates in high-risk groups, including those undergoing valve procedures and those treated for heart attacks. Perhaps surprisingly, the medication also appeared to act as a stabilizer for the heart's rhythm, drastically reducing the chance of developing new-onset atrial fibrillation, a common and troublesome irregular heartbeat that often follows heart surgery. The researchers noted that one specific drug in this class, dapagliflozin, showed the most consistent and reliable results across different studies, suggesting that not all drugs in this family may work exactly the same way in the short term.
Crucially, the safety profile of continuing these medications appeared favorable. The fear that keeping patients on the drug would lead to a surge in diabetic ketoacidosis, a serious condition where the body produces too many acids, was not supported by the data. In the entire collection of studies, this dangerous complication was extremely rare, occurring in only a single instance among hundreds of patients who continued their medication, with no increase in low blood sugar or the need for repeat surgeries. The evidence suggests that for many stable patients, the routine practice of stopping these medications before surgery may be unnecessary and could potentially remove a layer of protection the body needs during the stress of an operation. While the authors emphasize that individual patient needs must always be weighed carefully, this comprehensive review provides strong support for a more personalized approach, where doctors consider continuing these therapies to safeguard the heart and kidneys during the critical perioperative period.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.